16 recruiting, 9 completed, 8 terminated, 7 unknown. 36 Phase 1, 24 Phase 2, 1 Phase 3.
Follow Locally Advanced Solid Tumor: new trials by email Literature Review of Locally Advanced Solid Tumor trials Research Report on Locally Advanced Solid Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors 5 Azacytidine, Pembrolizumab, Nivolumab - Solid Tumor, Locally Advanced Solid Tumor | Phase 1 | Recruiting | Mohammed Milhem | 35 | 2026-02-11 | 2026-05-28 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours IPN60300 - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Recruiting | Ipsen | 114 | 2025-12-05 | 2026-10-01 |
| Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors YH32364 - EGFR Overexpression, Locally Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Yuhan Corporation | 80 | 2025-06-12 | 2026-06-10 |
| Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors VC004 Capsules - Locally Advanced Solid Tumor | Phase 3 | Recruiting | Jiangsu vcare pharmaceutical technology co., LTD | 54 | 2025-03-17 | 2026-07-27 |
| CD8 PET Imaging in Metastatic Solid Tumours 89Zr-Df-crefmirlimab PET scan, Nivolumab, Cetrelimab - Locally Advanced Solid Tumor | Phase 2 | Recruiting | University Medical Center Groningen | 30 | 2025-03-11 | 2026-02-09 |
| Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors Topical Tretinoin, Placebo - Metastatic Solid Tumor, Locally Advanced Solid Tumor | Phase 2 | Recruiting | University of Utah | 25 | 2025-02-19 | 2026-02-13 |
| IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors IBI3001 - Locally Advanced Solid Tumor | Phase 1 | Recruiting | Fortvita Biologics (USA)Inc. | 250 | 2025-01-10 | 2026-09-25 |
| A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors XL495, ADC cytotoxic agents - Solid Cancers, Solid Tumor Cancer | Phase 1 | Terminated | Exelixis | 9 | 2024-10-17 | 2025-06-25 |
| ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) Cyclophosphamide, Fludarabine, ACE2016 - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Recruiting | Acepodia Biotech, Inc. | 30 | 2024-08-22 | 2025-07-01 |
| Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors Lattice therapy (LRT) - Cancer, Metastatic Cancer | Phase 2 | Recruiting | University of Cincinnati | 37 | 2024-08-02 | 2026-05-04 |
| A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) NVL-330 - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Recruiting | Nuvalent Inc. | 200 | 2024-07-18 | 2026-10-20 |
| A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer [177Lu]Lu-SN201 - Solid Tumor, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | Spago Nanomedical AB | 90 | 2023-12-06 | 2025-11-20 |
| Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation HMBD-001, Docetaxel, Nab-paclitaxel - Non-Small Cell Lung Cancer, Pancreatic Cancer | Phase 1 | Active not recruiting | Hummingbird Bioscience | 68 | 2023-09-06 | 2025-04-18 |
| A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN) Solid Tumor, Advanced Solid Tumor | Recruiting | Centro di Riferimento Oncologico - Aviano | 782 | 2023-05-26 | 2023-09-13 | |
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors TNG462, Pembrolizumab - Locally Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Tango Therapeutics, Inc. | 225 | 2023-05-26 | 2026-09-08 |
| FOG-001 in Locally Advanced or Metastatic Solid Tumors FOG-001, mFOLFOX-6, Nivolumab - Cancer, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Parabilis Medicines, Inc. | 619 | 2023-05-23 | 2026-10-07 |
| A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations TY-2136b - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Unknown | TYK Medicines, Inc | 282 | 2023-04-20 | 2023-04-24 |
| A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours ES014 - Solid Tumor, Locally Advanced Solid Tumor | Phase 1 | Active not recruiting | Elpiscience (Suzhou) Biopharma, Ltd. | 120 | 2023-02-24 | 2026-10-19 |
| A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors TST003 - Locally Advanced Solid Tumor, Metastatic Tumor | Phase 1 / Phase 2 | Active not recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 111 | 2023-02-08 | 2026-09-29 |
| A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab NTX-1088, Pembrolizumab - Cancer, Tumor, Solid | Phase 1 | Active not recruiting | Nectin Therapeutics Ltd | 90 | 2022-09-01 | 2026-04-30 |
Showing 20 of 46. Sign in to see all of them.
Neoplasm Metastasis (36) · Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (6) · Breast Neoplasms (5) · Pancreatic Neoplasms (5) · Colorectal Neoplasms (4) · Endometrial Neoplasms (4) · Head and Neck Neoplasms (4) · Melanoma (4) · Ovarian Neoplasms (4) · Sarcoma (4) · Stomach Neoplasms (4) · Urinary Bladder Neoplasms (4) · Uterine Cervical Neoplasms (4) · Carcinoma, Hepatocellular (3)
Neoplastic Processes (36) · Pathologic Processes (36) · Pathological Conditions, Signs and Symptoms (36) · Neoplasms (33) · Neoplasms by Site (16) · Neoplasms by Histologic Type (13) · Neoplasms, Glandular and Epithelial (11) · Carcinoma (10) · Digestive System Diseases (10) · Digestive System Neoplasms (10) · Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Urogenital Diseases (10) · Urogenital Neoplasms (10) · Gastrointestinal Diseases (9)
pembrolizumab (7) · Nivolumab (4) · Oxaliplatin (3) · Cyclophosphamide (2) · Injections (2) · S 1 (combination) (2) · Trastuzumab (2) · fludarabine (2) · 130-nm albumin-bound paclitaxel (1) · Ado-Trastuzumab Emtansine (1) · Azacitidine (1) · Bevacizumab (1) · Capecitabine (1) · Cetuximab (1) · Docetaxel (1)
Nuvalent Inc. (3) · Acepodia Biotech, Inc. (2) · Ascendis Pharma Oncology Division A/S (2) · Jiangsu vcare pharmaceutical technology co., LTD (2) · Tango Therapeutics, Inc. (2) · Adlai Nortye Biopharma Co., Ltd. (1) · Aiping Zhou (1) · Centre Leon Berard (1) · Centro di Riferimento Oncologico - Aviano (1) · Compass Therapeutics (1) · Curon Biopharmaceutical (Australia) Co Pty Ltd (1) · EMD Serono (1) · Elevation Oncology (1) · Elpiscience (Suzhou) Biopharma, Ltd. (1) · Exelixis (1)
United States (30) · Australia (11) · Spain (9) · China (7) · South Korea (7) · Canada (6) · France (6) · Taiwan (6) · Italy (5) · Netherlands (4) · Belgium (3) · Singapore (3) · United Kingdom (3) · Germany (2) · Japan (2)
Apostolia Tsimberidou, MD, PhD (1) · Benjamin Oshrine (1) · Christopher Nevala-Plagemann, MD (1) · Davis Torrejon-Castro (1) · Elisabeth G.E. de Vries, MD, PhD (1) · Fabio Puglisi, MD, PhD (1) · Gary Richardson (1) · Karim Malek, MD (1) · Kim Taubman (1) · Maxim Pimkin, MD, PhD (1) · Maxim Pimpkin, MD (1)
PMID 20595147, PMID 21784628, PMID 25175099, PMID 25695221, PMID 28408243, PMID 29151359, PMID 29290249, PMID 29438373, PMID 35817480, PMID 36123697, PMID 36701651, PMID 37279836, PMID 38167937, PMID 38172595, PMID 39756156, PMID 39956770, PMID 41428976, PMID 42351304, PMID 42371780
2025 (1)